Introduction: When Sexual Function, Prostate Symptoms, and Hormones Collide
Erectile dysfunction and lower urinary tract symptoms related to benign prostatic hyperplasia often arrive together in the same patient, usually with the quiet confidence of conditions that know they are common. In aging men, this overlap is not surprising. The same years that increase prostate volume may also reduce vascular elasticity, alter metabolic health, lower testosterone levels, and weaken erectile performance. The clinical challenge is that these problems rarely appear as isolated textbook chapters. They appear as one man, in one consultation, asking why his urinary stream is poor and his erections are unreliable.
The study “Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for LUTS/BPH” addressed a practical question that matters in daily urology: does a low baseline total testosterone level reduce the sexual benefit of tadalafil 5 mg once daily in men with LUTS/BPH and erectile dysfunction? The investigators performed an integrated analysis of three randomized, double-blind, placebo-controlled trials, including more than 1000 men treated with tadalafil or placebo for 12 weeks.
The answer was clinically important and somewhat reassuring. Low total testosterone, defined as below 300 ng/dL, did not meaningfully impair the erectile response to once-daily tadalafil. Men with low and normal testosterone levels both improved significantly compared with placebo. This finding challenges the overly simple assumption that tadalafil will not work unless testosterone is normal. Biology, fortunately, is sometimes less pessimistic than our assumptions.
Why Testosterone Matters — But Not Always in the Way Patients Expect
Testosterone plays a real role in male sexual physiology. It supports libido, nitric oxide synthase expression, erectile tissue health, mood, muscle mass, and broader metabolic function. When testosterone is severely low, sexual desire may decline, erections may weaken, fatigue may increase, and overall well-being may deteriorate. No serious clinician should dismiss testosterone as irrelevant.
However, erectile dysfunction is rarely caused by testosterone alone. In many aging men, ED reflects a combination of endothelial dysfunction, vascular disease, diabetes, hypertension, obesity, medication effects, psychological stress, sleep disturbance, and relationship factors. Testosterone is one actor in the play, not the entire cast. Treating every erection problem as “low T” is medically lazy and commercially convenient, which is not a flattering combination.
The controversy has persisted because some studies suggested that men with low testosterone respond less well to phosphodiesterase type 5 inhibitors, and that testosterone replacement therapy may improve PDE5 inhibitor response in hypogonadal men who previously failed treatment. This created a clinical habit in some settings: check testosterone, correct testosterone, then prescribe PDE5 inhibitors. The problem is that this sequence may delay effective therapy for many men who could benefit immediately from tadalafil.
The integrated analysis examined precisely this issue. It excluded men taking testosterone replacement therapy, thereby reducing a major confounder. It then compared tadalafil response in men with low versus normal total testosterone and also considered luteinizing hormone levels. The result was clear: baseline total testosterone status did not significantly alter tadalafil’s benefit on erectile function and most sexual function domains.
Tadalafil 5 mg Once Daily: A Dual-Purpose Strategy for LUTS/BPH and ED
Tadalafil is distinctive among PDE5 inhibitors because it is approved not only for erectile dysfunction but also for lower urinary tract symptoms associated with benign prostatic hyperplasia. This dual role makes it especially relevant for aging men who present with both urinary and sexual complaints. Rather than treating the prostate in one lane and erectile function in another, tadalafil offers a single pharmacological bridge between the two.
Its mechanism begins with inhibition of PDE5, which preserves cyclic guanosine monophosphate signaling. In penile tissue, this enhances smooth muscle relaxation and supports arterial inflow during sexual stimulation. In the lower urinary tract, PDE5 inhibition may influence smooth muscle tone, pelvic blood flow, afferent nerve activity, and local signaling within the prostate and bladder neck. The result is not a dramatic prostate shrinkage, but a functional improvement in symptoms for selected patients.
Daily dosing changes the patient experience. With on-demand therapy, the man must plan medication around sexual activity. With tadalafil 5 mg once daily, the treatment becomes part of the background physiology. For many men, this reduces performance pressure and makes intimacy feel less like a scheduled pharmacology experiment. That psychological relief is not trivial.
In the analyzed trials, men were treated for 12 weeks with tadalafil 5 mg once daily or placebo. The study population included men at least 45 years old with LUTS/BPH, and many also reported erectile dysfunction. Baseline hormone measurements included total testosterone and luteinizing hormone. The investigators then assessed sexual response using International Index of Erectile Function domain scores, including erectile function, intercourse satisfaction, orgasmic function, overall satisfaction, sexual desire, and sexual confidence.
What the Integrated Analysis Found
The integrated population included 1075 men, with 540 randomized to tadalafil and 535 to placebo. Most were older white men, with mean ages generally in the mid-to-late sixties. The median baseline total testosterone level was approximately 355 ng/dL, and about one-third of men had total testosterone below 300 ng/dL. This matters because low testosterone was not a rare outlier; it was common enough to make the analysis clinically meaningful.
Men with low testosterone had more comorbid disease. Diabetes, cardiovascular disease, and hypertension were numerically more common in men with low total testosterone than in men with normal levels. This is consistent with what clinicians see every day: low testosterone often travels with metabolic and vascular risk. It may be a contributor, a consequence, or both. Either way, it marks a patient population that deserves careful cardiometabolic attention.
Baseline erectile function scores were slightly lower in men with low testosterone and in men with high luteinizing hormone, but these differences were not large enough to dominate the treatment response. After 12 weeks, tadalafil significantly improved most IIEF domain scores compared with placebo. Importantly, the improvement occurred in both testosterone subgroups.
The minimally clinically important difference analysis was particularly practical. Among men with total testosterone below 300 ng/dL, 57% of tadalafil-treated patients achieved a clinically meaningful erectile function improvement, compared with 26% receiving placebo. Among men with total testosterone at or above 300 ng/dL, 53% of tadalafil-treated patients achieved this threshold, compared with 29% receiving placebo. In other words, tadalafil worked in both groups, and low testosterone did not erase the benefit.
Clinical Meaning: Do Not Delay Treatment Unnecessarily
The most useful clinical message is straightforward: in older men with LUTS/BPH and erectile dysfunction, tadalafil 5 mg once daily can be started without waiting for proof that testosterone is normal. This does not mean testosterone testing is useless. It means that low total testosterone, especially mild-to-moderate reduction, should not automatically be treated as a barrier to PDE5 inhibitor therapy.
This is important because delays in ED treatment can worsen anxiety, relationship tension, and avoidance behavior. A patient who finally raises the issue of erectile dysfunction may already have waited months or years. Telling him to wait longer while hormone testing is repeated, interpreted, and possibly treated may not be necessary if tadalafil is otherwise appropriate.
The study also supports a more disciplined approach to testosterone replacement therapy. TRT should not be added casually to every man with ED and a borderline testosterone value. Testosterone therapy has indications, monitoring requirements, and risks. It should be reserved for men with consistently low testosterone levels, compatible symptoms, and an appropriate clinical context.
A sensible approach is to treat the erectile and urinary symptoms with tadalafil when indicated, while evaluating testosterone separately and carefully. If the patient has severe hypogonadal symptoms, repeatedly low morning testosterone, low libido, anemia, reduced muscle mass, osteoporosis, or other signs of androgen deficiency, testosterone therapy may be considered according to guidelines. But tadalafil does not need to sit in the waiting room until testosterone receives permission.
Where the Evidence Requires Caution
The findings are reassuring, but they should not be exaggerated. The analysis defined low testosterone as less than 300 ng/dL. Men with very low testosterone levels were likely underrepresented because trial inclusion criteria may have excluded more complex endocrine disease. Therefore, the study cannot fully answer whether tadalafil works equally well in men with severe hypogonadism, such as total testosterone near or below 200 ng/dL.
Another limitation is that testosterone was measured only once at baseline. Testosterone levels fluctuate by time of day, sleep, illness, medications, obesity, and assay variability. A single value is useful for research grouping, but in clinical endocrinology, diagnosis usually requires repeat morning testing. One blood test should not become a lifelong label.
The study also measured total testosterone, not free testosterone. In older men, sex hormone-binding globulin changes can make total testosterone less reflective of biologically active androgen status. Some men with borderline total testosterone may have adequate free testosterone, while others may not. This matters when deciding whether symptoms truly reflect androgen deficiency.
Finally, the population consisted of men with LUTS/BPH, not exclusively men presenting primarily for ED. Some participants may have had mild or no erectile dysfunction at baseline, which could reduce the apparent magnitude of tadalafil’s erectile effect. Even so, the treatment benefit remained statistically and clinically relevant, making the conclusion stronger rather than weaker.
A Practical Treatment Framework for Clinicians
Men presenting with LUTS/BPH and erectile dysfunction deserve a structured evaluation rather than a reflex prescription. Clinicians should assess urinary symptom severity, erectile function, cardiovascular risk, diabetes status, medications, testosterone-related symptoms, prostate cancer risk when appropriate, and patient goals. The goal is not merely to improve a questionnaire score, but to restore function in a medically safe and meaningful way.
Tadalafil 5 mg once daily may be especially appropriate when urinary symptoms and ED coexist, when the patient values spontaneity, or when alpha-blocker-related sexual side effects are a concern. It may also appeal to men who dislike on-demand planning. However, it should not be used with nitrates, and cardiovascular status must be considered before prescribing any PDE5 inhibitor.
Hormone testing is still valuable in selected men. Morning total testosterone should be considered when symptoms suggest androgen deficiency, especially low libido, fatigue, reduced vitality, infertility concerns, decreased shaving frequency, gynecomastia, anemia, osteoporosis, or unexplained loss of muscle mass. If low, it should usually be repeated before diagnosis. Luteinizing hormone may help distinguish primary from secondary hypogonadism.
The practical takeaway is not “ignore testosterone.” It is “do not overestimate testosterone as the gatekeeper of tadalafil response.” Testosterone is important, but tadalafil can still work even when total testosterone is below the conventional threshold, particularly in the mildly low range represented in this study.
Conclusion: Tadalafil Works Across Testosterone Subgroups
The integrated analysis of three randomized controlled trials provides a clinically useful answer to a common question. In older men with LUTS/BPH and erectile dysfunction, baseline low total testosterone did not meaningfully reduce the sexual response to tadalafil 5 mg once daily. Men with low and normal testosterone levels both achieved significant improvements compared with placebo.
This finding should make clinical practice more efficient. Men with LUTS/BPH and ED can often begin tadalafil therapy at the initial consultation if there are no contraindications, while testosterone evaluation proceeds in parallel when clinically indicated. That approach respects both symptom relief and endocrine accuracy.
The study also reminds us that erectile dysfunction is not a one-hormone disease. It is vascular, neurological, psychological, metabolic, hormonal, and relational. Testosterone matters, but it does not hold a monopoly. Tadalafil remains a valuable option because it addresses the erectile pathway directly and, in men with LUTS/BPH, may improve urinary symptoms as well.
Good medicine does not force every patient through the same narrow doorway. It recognizes the overlapping biology, treats what can be treated now, and investigates what needs clarification. In this context, tadalafil is not waiting for testosterone’s approval—and for many men, that is excellent news.
FAQ
Does low testosterone stop tadalafil from working?
Not usually. In this integrated analysis, men with total testosterone below 300 ng/dL still responded significantly better to tadalafil 5 mg once daily than to placebo.
Should testosterone be checked before starting tadalafil?
It can be checked when symptoms suggest androgen deficiency, but tadalafil treatment does not necessarily need to be delayed while waiting for confirmation of normal testosterone.
Can tadalafil treat both ED and urinary symptoms from BPH?
Yes. Tadalafil 5 mg once daily is used for erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia in appropriately selected patients.
When is testosterone replacement therapy appropriate?
TRT should be considered only when low testosterone is repeatedly confirmed and symptoms are consistent with androgen deficiency. It should not be used casually as an automatic add-on to tadalafil.
What remains uncertain after this study?
The study does not fully answer whether tadalafil works equally well in men with very severe testosterone deficiency, because such patients were likely underrepresented.
